Novo Nordisk (NYSE: NVO) is under attack. Although the Denmark-based drugmaker is a pioneer and leader in the GLP-1 diabetes and weight loss drug markets, countless companies are trying to steal ...

Ozempic maker Novo Nordisk pushed out its chief executive after losing ground in the anti-obesity drug market, which has caused a steep stock-price decline and impatience at the nonprofit ...

Novo Nordisk A/S (NYSE: NVO) is one of the high-margin pharma stocks to buy now. Berenberg has reaffirmed its Hold rating on ...

What happened. Novo Nordisk (NVO-2.44%) might have one of the hottest products on pharmacy shelves right now, but its stock went cold on Thursday. Following a downbeat note from an analyst ...

Novo Nordisk and its chief executive are parting ways after recent market challenges and a sharp decline in the company's share price over the past 12 months. Lars Fruergaard Jorgensen, who has ...

Novo Nordisk is an excellent healthcare company to invest in. Although its valuation may not look cheap as the stock trades at 46 times its trailing earnings, there's a lot of long-term growth ahead.

The Danish pharmaceutical said it was ending the partnership because Hims is selling and promoting a cheaper copycat of its ...

Shares of Novo Nordisk (NYSE: NVO) are tumbling on Monday, down 5.6% as of 2:11 p.m. ET. The drop comes as the S&P 500 ... Before you buy stock in Novo Nordisk, consider this: ...

Novo Nordisk and its chief executive are parting ways after recent market challenges and a sharp decline in the company's share price over the past 12 ... This Stock Is Cheap, High-Yielding, ...

Novo Nordisk has a GLP-1 Ozempic pill. That's both good and bad news for Novo Nordisk stock. Skip to main content. Boydton, VA. Boydton, VA. Local News. Subscriptions; Animals. Finance ...